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ABSTRACT
There are many biological activities attributed to isoflavonoids. The majority of them could be beneficial and some of them may be 
detrimental, depending on specific circumstances. Isoflavonoids play an important role in human nutrition as health promoting natu-
ral chemicals. They belong to plant secondary metabolites that mediate diverse biological functions through numerous pathways. 
They are structurally similar to estrogens, exerting both estrogenic and antiestrogenic properties in various tissues. The results of 
epidemiologic studies exploring the role of isoflavonoids in human health have been inconclusive. Some studies support the notion 
of a protective effect of their consumption in immunomodulation, cognition, risk reduction of certain cancers, cardiovascular and 
skin diseases, osteoporosis and obesity, as well as relief of menopausal symptoms. Other studies failed to demonstrate any effects. 
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Ørgaard and Jensen, 2008; Sabudak and Guler, 2009), there 
is growing evidence from human dietary and epidemiologic 
studies that the role of isoflavonoids in human health is 
questionable. Some studies speak in favor of a protective 
effect of isoflavonoid consumption as dietary supplements 
and as a natural alternative to estrogen replacement therapy, 
other studies failed to demonstrate favorable effects. The 
aim of this article is not to present a comprehensive review 
of the literature but to provide a critical review of the argu-
ments centered on a variety of effects and mechanisms of 
isoflavonoid actions. 
Natural sources, bioavailability and metabolism
Isoflavonoids, as plant secondary metabolites, pos-
sess a  3-phenylchroman skeleton that is biogenetically 
deriv ed fr o m 2- p h en yl chr o man sk el eto n o f  fla v o n o i ds.  
Isoflavonoids are particularly prevalent in Papilonoidae, 
subfamily of Leguminosae (Dixon and Summer, 2003). 
Soy (Glycine max) principle isoflavones genistein, daid-
zein and glycitein are the aglycones with three possible 
glycoside forms: β-D-glycoside, 6΄΄-O-malonyl-glycoside 
and a 6΄΄-O-acetyl-glycoside. However, primarily they are 
naturally present in their β-D-glycoside form as genistin, 
daidzin, glycitin. The aglycone form of isoflavones is bio-
logically active. In addition to soy, isoflavone daidzein and 
genistein, their precursors formononetin, biochanin A, their 
Introduction
Interest in possible health benefits of isoflavonoids has 
increased due to a variety of bioprotective effects, including 
antioxidant, antimutagenic, anticarcinogenic, antiprolif-
erative activities, mostly assessed in vitro (Birt et al., 2001; 
Miadokova et al., 2002; Ryan-Borchers et al., 2006; Iwasaki 
et al., 2008; Scarpato et al., 2008). Isoflavonoids have been 
classically defined as dietary antioxidants, i.e. compounds 
that may protect against oxidative stress linked to inflam-
mation and the risk of macromolecule damage by free 
radicals and by related oxygen and nitrogen-based oxidizing 
agents (Reiter et al., 2008). They may protect the body from 
hormone-related cancers, like breast, endometrial (uterine) 
and prostatic. Despite the wide spectrum of health protec-
tive abilities that have been attributed to them, e.g. immu-
nomodulation, risk reduction of chronic diseases including 
cardiovascular diseases, diabetes, cancer, osteoporosis and 
obesity (Bezek et al., 2008), as well as relief of menopausal 
symptoms (Birt et al., 2001; Ryan-Borchers et al., 2006; 
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glycosides, glycosides malonates and acetyl glycosides were 
determined in red clover (Trifolium pratense) extracts using 
chromatographic and spectrometric methods (Sabudak and 
Guler, 2009). Murata et al. (2006) isolated from leaves of 
Millettia taiwaniana (Leguminosae) two new isoflavonoids, 
millewanin-F and furowanin-A, together with previously 
known five isoflavonoids. The bioavailability of isoflavones 
has been shown to be influenced by their chemical form 
in foods (generally glycoside conjugates), susceptibility to 
degradation, the microbial flora of the consumer, and by the 
food matrix. Bioavailability of isoflavonoids may depend to 
some extent upon interaction with other dietary compo-
nents (Birt et al., 2001).
The metabolism of isoflavones in animals and humans 
is complex and is a combination of mammalian and gut 
microbial processes. Moreover, there is a  great deal of 
individual variability in the metabolism of isoflavonoids. 
Individual differences in gut microflora, intestinal transit 
time, and genetic polymorphisms, all are likely to contribute 
to this great variability (Duffy et al., 2007). During digestive 
and absorptive processes, isoflavonoids often undergo met-
abolic transformations. In some individuals, daidzein can 
be converted by the intestinal microflora to the metabolite 
equol or to O-desmethylangolensin, and genistein to p-ethyl 
phenol. 
The degree of absorption of bioflavonoids has been the 
subject of frequent debates among scientists. Absorption 
and bioavailability of isoflavonoids is much higher than 
originally believed. Cesarone et al. (2009) compared absorp-
tion of an isotonic isoflavonoid solution vs. tablet form with 
the equivalent amount of fluid and revealed a dramatically 
accelerated bioavailability of isoflavonoids delivered in an 
isotonic formulation. 
Under certain nutritional conditions total isoflavone 
concentrations can be measured in urine, plasma and even 
in breast fluid. Assessment of isoflavonoids in nipple aspi-
rate fluid enables to elucidate their effect directly on breast 
tissue (Maskarinec et al, 2008a). 
The hypothesis that isoflavones are absorbed more 
efficiently from fermented than from non-fermented soy 
foods was re-examined and then rejected (Maskarinec et 
al., 2008b). Therefore recommendations favoring fermented 
soy foods are not justified when the intestinal microflora is 
capable of hydrolyzing the isoflavone glycosides from non-
fermented soy foods. 
Estrogenic activity of isofl  avonoids
Isoflavones are diphenolic compounds that are structurally 
or functionally similar to endogenous estrogens and display 
agonistic and antagonistic interactions with estrogen recep-
tors (Wang et al., 2008). Their biological activity is partly 
ascribed to the structural similarities with the primary 
physiologically relevant estrogen – 17β-estradiol (E2). They 
bind to and activate intracellular estrogen receptors: ERα and 
ERβ and, mimicking the effects of estrogen, are commonly 
referred to as phytoestrogens. In most systems, the relative 
binding affinities of genistein and daidzein are greater for 
ERβ than for ERα, while E2 binds to both receptors with 
approximately equal affinities (Messina et al., 2006). The 
estrogenic activities of soy isoflavones are thought to play 
an important role by their health-enhancing properties 
in menopausal symptoms and in treating osteoporosis 
(Lockwood, 2008). Though isoflavonoids have exhibited 
estrogen-like properties they are bound more weakly to 
estrogen receptors than E2. Arguments have been presented 
for considering soy isoflavones as natural selective estrogen 
modulators. 
Controversal data on estrogen-like eff  ects
Since overexposure to estrogen is a major contributing factor 
in the development of breast cancer, the relationship between 
soyfoods and breast cancer has become controversial. A 
concern has been raised that soy-derived isoflavones, which 
exhibit estrogen-like properties under certain experimental 
conditions, may stimulate the growth of existing estrogen-
sensitive tumors. This concern exists because of evidence 
showing that isoflavones bind and transactivate estrogen 
receptors and elicit estrogenic effects in rodent reproductive 
tissues. Limited human data directly address the tumor-
promoting effects of isoflavonoids (Messina et al., 2006) 
The fact that genistein at low physiologically relevant 
levels may stimulate estrogen receptor positive tumors can 
be attributed to its estrogenic properties, while at higher 
levels, anticancer actions of isoflavonoids may predominate 
(Duffy et al., 2007). 
Estrogen-like effects have raised concern regarding soy/
isoflavone consumption particularly in the case of post-
menopausal women at high risk of breast cancer. Currently 
there is little evidence to suggest that any potential weak 
estrogenic effects of dietary isoflavones have a clinically 
relevant impact on the breast tissue in healthy women or 
breast cancer survivors (Messina and Wood, 2008). 
 Epidemiologic evidence shows that higher soy intake in 
Asian women is associated with a nearly one-third reduction 
in breast cancer risk and that Japanese breast cancer patients, 
in comparison to Western women, exhibit better survival 
rates even after controlling stage of diagnosis. Evaluation 
of the short-term effects of high-dose soy isoflavonoid 
supplements on reproductive tissues in a postmenopausal 
primate model showed that high doses of dietary isoflavo-
noids had minimal uterotrophic or mammotrophic effects 
(Wood et al., 2006). These findings suggest that comparable 
high-dose isoflavonoid supplements, in particular those 
containing equol or taken by equol producers, would have 
minimal negative estrogenic effects on human reproductive 
tissues and are not likely to contribute to increased uterine 
or breast cancer risks. 
Since endogenous estrogens are important determinants 
of breast cancer risk in postmenopausal women, Wood et 
al. (2007) evaluated the effects of dietary soy isoflavonoids 
on endogenous metabolism in a postmenopausal primate 
model. They revealed that isoflavonoid treatment did not 
significantly alter gene markers of estrogen metabolism or 
estrogen receptor agonist activity in breast tissue. 213
Also available online on setox.eu/intertox & versita.com/science/medicine/it
Interdisciplinary Toxicology. 2009; Vol. 2(4): 211–218
Copyright © 2009  Slovak Toxicology Society SETOX
On the other hand, there are data supporting the idea 
that a high dietary isoflavone intake improves the prognosis 
of breast cancer patients. For example, among postmeno-
pausal U.S. breast cancer patients, mortality was reduced 
due to isoflavonoid diet (Fink et al., 2007). Available data 
for estrogen therapy effects on breast cancer recurrence and 
mortality provide some assurance for breast cancer patients 
that isoflavone supplements, when taken at dietary levels, do 
not contribute to recurrence rates. Nevertheless more data 
are needed to better address this issue (Messina and Wood, 
2008).
Phytoestrogens and eff  ects on gene expression
Isoflavones can exert hormonal and nonhormonal proper-
ties in many ways. Isoflavones have been shown to inhibit 
the activity of enzymes involved in estrogen metabolism. 
Estrogens have diverse effects throughout the body, attrib-
utable in part to their ability to modulate transcription of 
target genes in a variety of organs. Rice et al. (2006) found 
that phytoestrogens and their low dose combinations inhib-
ited mRNA expression and activity of aromatase in human 
granulosa-luteal cells. Due to the established association 
between estrogen levels and breast cancer risk, the inhibi-
tory effect of biochanin A  on enzyme aromatase, the protein 
product of CYP 19 gene, was studied. Investigation of the 
effect on gene regulation and enzyme activity of aromatase 
showed that this isoflavonoid inhibited CYP19 expression 
and aromatase activity and hampered the growth of MCF-7 
breast carcinoma cells attributed to the enzyme activity 
(Wang et al., 2008). 
At nutritionally relevant doses, phytoestrogens may 
selectively interact with ERβ and thus affect only expres-
sion of a subset of estrogen- responsive genes. Different 
regulation of estrogen-responsive genes by isoflavonoids 
may also depend upon the relative ratio of ERα and ERβ 
present within tissue types. To test the hypothesis that soy 
isoflavones selectively trigger Erβ-dependent gene expres-
sion, which may be particular to the cell type and dependent 
on relative expression of ERα and Erβ, Chrzan and Bradford 
(2007) studied whether genistein and daidzein could affect 
reporter gene transcription via the estrogen receptors ERα   
and ERβ1. They documented that both phytoestrogens, 
genistein and daidzein, increased the expression of estrogen-
responsive genes in human MCF-7 breast carcinoma cells. 
Data from experiments using DNA microarray analysis 
for examining the effects of genistein in the developing rat 
uterus indicate that genistein alters the expression of 6–8 
times as many genes as does physiological estrogen E2. 
Genistein affected 227 genes, the majority of which were 
down regulated (Barnes, 2004). 
Emerging research using genomics and proteomics 
enabled to understand the participation of enzymes 
included in the isoflavonoid metabolic pathway regulation. 
Ralston et al., (2005) cloned and functionally characterized 
soybean chalcone isomerases (CHIs), key enzymes in the 
phenylpropanoid pathway that produces flavonoids and iso-
flavonoids. Gene expression and kinetics analyses revealed 
that the gene expression for soybean type I CHI, which uses 
naringenin chalcone as substrate, is coordinately regulated 
with other isoflavonoid-specific genes, while the legume 
specific type II CHIs, which uses a variety of chalcone 
substrates, are coordinately regulated with an isoflavonoid-
specific gene and specifically activated by nodulation 
signals. Comparison of putative soybean CHI with CHI 
ortologs from other species showed that their amino acid 
sequences fell into four different subfamilies. CHIs in the 
first subfamily (CHI1) were found only in legumes and were 
similar at least in 70% to those in Plant Genome Database 
(Ralston et al., 2005).
Inconsistency between phytoestrogen 
intake and risk for colorectal cancer
Some experimental studies reported that anticarcinogenic 
properties of dietary soy isoflavonoids play an important 
role in preventing colorectal cancer. However, few epide-
miologic studies have examined this association in general 
populations and their findings have been inconsistent 
(Akhter et al., 2008). 
Investigation of the association between dietary isofla-
vone intake and incidence of colorectal cancer in a prospec-
tive cohort study of 83,063 Japanese men and women docu-
mented that the intake of isoflavones was not associated with 
the risk of distal colorectal and rectal cancers in either men 
or women. Moreover, the risk of proximal colon cancer in 
men decreased with increasing consumption of isoflavones, 
miso soup and soy food (Akhter et al., 2008). These find-
ings are in accordance with those aimed at soy isoflavones 
modulation of rat colon carcinogenesis because pre- and 
postnatal exposure to dietary soy isoflavones suppressed 
the growth of colon tumors in male rats (Raju et al., 2009). 
Inconsistency between phytoestrogen 
intake and risk for breast cancer
Data regarding the role of isoflavonoids in breast cancer 
prevention are conflicting. Nevertheless, they suggest that 
early exposure in childhood or early adolescence may be 
protective (Ju et al., 2006; Duffy et al., 2007). There has 
been some evidence suggesting that the menopausal status 
of women may modulate the effect of isoflavonoids. Case-
control studies examining phytoestrogens and breast cancer 
incidence have generally found more evidence for a protec-
tive role in premenopausal women versus postmenopausal 
ones because isoflavonoid effects are dependent on the 
hormonal status of the woman, with stimulatory effects in 
low-estrogen environments, while in high-estrogen states 
they may block the effects of estrogen.
There are in vivo animal data suggesting that genistein 
may interfere with inhibitory effects of tamoxifen on breast 
cancer cell growth (Liu et al., 2005). Several studies using 
urine serum concentrations of phytoestrogens and their 
metabolites as biomarkers of their intake reported reduced 
risk for breast cancer among breast cancer survivors, yet 214
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other studies have failed to show an effect of phytoestrogens 
on breast cancer risk or on the menopausal syndrome (Duffy 
et al., 2007). Recently Goodman et al. (2009) examined the 
association of urinary phytoestrogens with the risk of post-
menopausal breast cancer and results of their multiethnic 
cohort study revealed that a diet rich in isoflavones from 
soy products reduced the risk of postmenopausal breast 
cancer, particularly in populations with comparatively 
high excretion of phytoestrogens. Iwasaki et al., (2008) also 
found a statistically significant inverse association between 
plasma genistein and the risk of breast cancer. 
Some differences in the results presented could be 
related to other abettors, such as genetic factors which may 
modulate the effect of phytoestrogens (Piller et al., 2006). 
Functional polymorphism in genes that encode for enzymes 
involved in the estrogen biosynthesis and metabolism and 
in genes that encode hormone receptors may have been 
associated with the risk for breast cancer (Atkinson et al., 
2004). But no association between a polymorphism in genes 
CYP17  (5´untranslated  MspA1 polymorphism), CYP19 
(generated by a G → T substitution in intron 6), involved 
in the sex hormone biosynthesis pathway, and Pvull 
(lipoprotein lipase) polymorphism (generated by a C → T 
substitution in intron 1) in the estrogen receptor ESR1 gene 
and the risk of breast cancer was demonstrated (Chen et al., 
2008). Piller et al. (2006) examined dietary genistein intake, 
CYP17 5´untranslated MspA1 genetic polymorphism and 
breast cancer risk in premenopausal breast cancer patients. 
The risk-reducing effect of genistein consumption was not 
modified by CYP 17 genotype. On the other hand, examina-
tion of two single nucleotide polymorphisms in Cyp 19 gene 
(aromatase), rs1008805 (A/G) and rs730154 (C/T) revealed 
that premenopausal women carrying at least one G alelle 
at  Cyp 19 locus was associated with an increased breast 
cancer risk (Talbot et al., 2008). Furthermore, Cyp17 variant 
C alelle may increase the breast cancer risk in conjugation 
with long-term hormone replacemet treatment (HRT) and 
a high body mass index (BMI) in postmenopausal women 
(Chen et al., 2008). These findings support the potential 
role of variation in estrogen biosynthesis genes in premeno-
pausal and postmenopausal breast cancer risks. 
Additionally, results obtained by Boccia et al. (2005), 
proved that SULTA1Arg213His gene (encoding sulfotrans-
ferase) polymorphism is a potential marker for identifying 
gastric cancer individuals at a high-risk, and useful in 
defining who may benefit from specific chemopreventive 
interventions. 
Proposed mechanisms for cancer prevention
Isoflavonoids have been shown to possess many bio-
logical properties that may account for cancer prevention. 
Isoflavones exert their effects through numerous pathways 
and with respect to cancer prevention, they use mechanisms 
of action which appear to be various, complementary and/
or overlapping. 
Some mechanisms of action have been identified for iso-
flavone/flavone prevention of cancer, including estrogenic/
antiestrogenic activity, antiproliferation, induction of cell 
cycle arrest and apoptosis, prevention of oxidation, induc-
tion of detoxification enzymes, regulation of host immune 
system and changes in cellular signaling (Birt at al., 2001; 
Murata  et al., 2006; Chrzan and Bradford, 2007). It is 
expected that also combinations of these mechanisms may 
contribute to cancer prevention. 
Dysregulated proliferation appears to be a hallmark of 
an incerased susceptibility to neoplasia. Cancer preven-
tion is generally associated with inhibition, reversion or 
retardation of cellular hyperproliferation. It is known that 
dietary isoflavonoids may behave as general cell inhibi-
tors. Although most isoflavonoids appear to be non-toxic 
to humans and animals, they have been shown to inhibit 
proliferation, the cell cycle or induce apoptosis in many 
kinds of cultured cancer cell lines. It was thus found that 
check points at both G1/S and G2/M of the cell cycle were 
perturbed by isoflavonoids (Birt at al., 2001).
Soy-protein-derived isoflavonoids have antiproliferative 
and proapoptic effects on prostatic epithelial cells in vitro 
and on the prostate gland of macaques, preventing prostate 
cancer development and/or progression in animal popula-
tions consuming soy protein (Hedlund et al., 2005; Perry et 
al., 2007). Activation of Erβ is supposed to result in decreased 
proliferation due to the receptor expression loss because Erβ 
probably functions as tumor suppressor within the prostate 
gland. The Erβ expression loss in prostatic adenocarcinoma 
was shown to result from an epigenetic effect – gene silenc-
ing caused by promoter methylation (Perry et al., 2007). 
Gene silencing due to promoter methylation provides an 
opportunity for clinical intervention, as gene-re-expression 
can be induced by a variety of DNA demethylating agents.
Apoptosis, i.e. natural programed cell death, is a physi-
ological phenomenon indispensable for normal functioning 
of the organisms. The signal to apoptosis can be started 
practically in any cell. Disturbance in apoptosis regulation 
determines the essential link in the pathogenesis of many 
diseases, including cancer. Recent studies have shown, that 
genistein has multiple effects because it induces apoptosis 
also by mechanisms that do not involve ERs, as demon-
strated in HepG2 cells, which do not express ERs (Chodon 
et al., 2007; Ørgaard and Jensen, 2008). 
On trying to explain molecular mechanisms of apoptosis 
induction in human leukemia HL-60 cells by isoflavonoids 
from the leaves of Milettia taiwaniana, Murata et al. (2006) 
and Ito et al. (2006) found that isoflavonoids induced apop-
tosis through activation of the caspase-9/caspase-3 pathway 
which is triggered by mitochondrial dysfunction.
The biological mechanism by which phytoestrogens, 
particularly in the Western diet, can protect against 
hormone-dependent breast cancer is likely through their 
competitive effects on the generation, transport and removal 
of endogenous steroid hormones (Piller et al., 2006). By 
competing for estrogen receptors, phytoestrogens possibly 
inhibit binding of the more potent endogenous estrogens 
and decrease their potential effects on breast cancer risk 
(Verheus et al., 2007). They may inhibit also proliferation 
of hormone-independent breast cell lines via a number of 
mechanisms, including inhibition and down-regulation 215
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of protein tyrosine kinases, which are involved in growth 
signaling pathways. Genistein was shown to inhibit tyrosine 
kinase, particularly the autophosphorylation and activation 
of epidermal growth factor receptor, which is important in 
regulating apoptosis and cell proliferation. Genistein inhib-
ited protein tyrosine kinase-dependent transcription of c-fos 
and subcellular proliferation in estrogen receptor negative 
human breast cancer cell lines. Key enzymes implicated in 
cancer invasion are also affected by genistein (Kousidou et 
al., 2006). 
Changes in cell signaling were demonstrated in the HC11 
mouse mammary epithelial cell line. Soy isoflavone genis-
tein upregulated epithelial adhesion molecule E-cadherin 
expression and attenuated β-catenin signaling in mammary 
epithelial cells. In addition, it diminished basal and Wnt-1- 
(wingless)-induced cell proliferation and attenuated Wnt-1 
targets c-Myc and cyclin D1 expression (Su and Simmen, 
2008).
Mammographic density as a 
biomarker for breast cancer risk
Isoflavonoids have been increasingly advocated as potential 
natural alternatives to hormone replacement therapy. There 
are however only limited data on the effect of isoflavones 
on breast density, despite the fact that isoflavonoids were 
proved to be present in breast fluids and could directly act 
on breast tissue (Maskarinec et al., 2008a). 
Although isoflavones have been suggested to protect 
against breast cancer, it is still not clear whether they act as 
estrogens or antiestrogens in breast tissue. Mammographic 
breast density, representing the amount of stromal and 
glandural tissue within the breast, has consistently been 
associated with a risk for breast cancer and a high density 
is often used as a predictive biomarker for breast cancer 
risk (Maskarinec et al., 2003). The mechanism underly-
ing this relationship has not been fully explained, but it 
has been proposed that breast cancer density provides 
an index of current and past hormonal and reproductive 
events that modulate the risk for breast cancer. A high 
mammographic density has been associated with a 3- to 
6-fold increase in breast cancer risk. Only few intervention 
studies with isoflavones and mammographic density have 
been published. In studies performed in premenopausal 
and postmenopausal women no effect of isoflavones from 
soy or other sources on mammographic density was shown 
(Maskarinec et al., 2003; Maskarinec et al., 2009). Neither 
did intervention studies with phytoestrogens from red 
clover or black cohosh show any statistically significant 
e f f e c t s  o n  m a m m o g r a p h i c  d e n s i t y  i n  p o s t m e n a p a u s a l  
women (Hirschberg et al., 2007). The findings in a 1-year 
double-blind, randomized, placebo-controlled trial did not 
support any effect (beneficial or adverse) of a large quantity 
of soy proteins containing isoflavones on mammographic 
density in postmenopausal women. The results of this trial 
do not support the hypothesis that a diet high in soy protein 
would decrease mammographic density in postmenopausal 
women (Verheus et al., 2008). 
Although it has been hypothesized that breast density 
reflexes cumulative exposure to estrogens, in postmeno-
pausal women the relationship between phytoestrogens and 
mammographic density may be different due to the decline 
of circulating levels of endogenous hormones after meno-
pause. Yet examination of the relation between circulating 
sex hormones and mammographic density showed that in 
postmenapausal women mammographic density was not 
dependent on circulating sex hormone levels (Tamini et al., 
2005; Elliassen et al., 2008). 
Atkinson et al. (2004) did not observe a significant effect 
of clover-derived isoflavone supplement, taken daily for 1 
year, on mammographic density in women aged 49–65 
years, unlike conventional estrogen replacement therapies. 
Furhermore, they did not find any effect of the isoflavone 
supplement on estradiol, follicle-stimulating hormone or 
luteinizing hormone in postmenopausal women, or on hot 
flushes or other menopausal symptoms. A study aimed at 
soy isoflavonoid effects on endogenous estrogen metabolism 
in postmenopausal female monkeys showed that long-term 
exposure to soy isoflavonoids did not significantly alter gene 
markers of estrogen metabolism or estrogen receptor ago-
nists in breast tissue. This long-term exposure may facilitate 
endogenous estrogen clearance and catabolism to more 
benign 2-hydroxylated metabolites (Wood et al., 2007). 
Combined hormone replacement therapy may be associ-
ated with an increased risk for breast cancer and an increase 
in mammographic breast density. Breast cancer density 
increases when a woman starts on hormone replacement 
therapy and decreases when she discontinues it. Breast 
density is also reduced by antiestrogenic effect of tamoxifen, 
a selective estrogen receptor modulator. 
Overall, recent epidemiologic and clinical data showed 
either a modest protective role or no effect of isoflavone 
intake on breast tissue density in pre- or postmenopausal 
women and on breast proliferation in postmenopausal 
women with or without a history of breast cancer (Messina 
and Wood, 2008).
Modulation of immune function
The isoflavone daidzein administered orally stimulated 
murine nonspecific immunity, activated hormoral immu-
nity, enhanced cell-mediated immunity, and at physi-
ologically relevant concentrations potentiated lymphocyte 
activation, suggesting that its immunostimulatory effects 
may be involved in cancer prevention (Birt et al., 2001). 
Equol is known to protect against solar-simulated UV 
radiation induced inflammation and immunosuppression. 
Two protective mechanisms are responsible: antioxidant 
actions and phytoestrogenicity. It is supposed that both 
might be functionally linked (Widyarini et al., 2006).
The role of the host immune function has become 
increasingly important in our understanding of the 
mechanisms involved in cancer prevention. The human 
immune system encompasses an array of defenses that help 
to guard against the development of age-related diseases, 
e.g. cancer. However, its function can be adversely affected 216
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by hormonal changes and oxidative damage (Kralova et al., 
2008). The immune system may be compromised mainly 
after menopause because of the effects of aging and dimin-
ishing concentration of estrogen, an immune-modulation 
hormone. The human immune system may benefit from 
various biological properties of isoflavonoids. Since post-
menopausal women are in particular susceptible to chronic 
disease associated with aging and to major shifts in hor-
monal status, isoflavones with estrogenic and antioxidant 
properties may offer immunologic benefits to women dur-
ing this stage of life. Ryan-Borchers et al. (2006) reported 
that soy isoflavones stimulated an increase of important 
markers of immunity – B cells in healthy postmenopausal 
women.
Although soy isoflavones have been suggested to have 
both immune-enhancing and immune-suppressive effects, 
their effects on allergic disorders are less clear. Nagata et 
al. (2008) showed that a high intake of soy isoflavones was 
associated with decreased risk of cedar pollinosis, the most 
common seasonal allergic rhinitis.
Eff  ect on oxidative stress markers
Besides their estrogenic activities, isoflavonoids also 
display nonhormonal actions such as antioxidant effects. 
Antioxidant properties are one of the most important 
claims for food ingredients, dietary supplements and anti-
cancer products. The antioxidant property of isoflavonoids 
offers an additional important mechanism through which 
they protect against chronic diseases. 
Genistein and dadzein isolated from soybean showed 
stronger antioxidant activity than their glycosides, and 
dadzein isolated from Pueraria lobata exhibited the same 
antioxidant activity as α-tocopherol (Cherdshewasart and 
Sutjit 2008). 
Cellular damage resulting from oxidative stress is 
supposed to be a major contributor to the etiology of car-
diovascular disease through low-density lipoprotein (LDL) 
cholesterol oxidation and to the development of cancer 
through DNA strand breaks induction. The antioxidative 
efficiency of dietary isoflavonoids is associated not only with 
their reductive capacity but also with their protein-binding 
properties. In humans isoflavones may prevent low-density 
lipoprotein LDL cholesterol oxidation and lower markers of 
DNA oxidative stress in vivo (Ryan-Borchers et al. 2006). 
Since isoflavonoids can behave as antioxidants and thus 
protect against diseases resulting from oxidative damage, 
they may play a substantial role in disease prevention in 
postmenopausal women.
Eff  ect on vascular function
The postmenopausal status increases cardiovascular risk 
due to accelerated atherosclerosis progression. Prevention 
of intracellular lipid deposition may inhibit the formation of 
atherosclerotic lesions at the primary stage of atherogenesis 
at the level of the arterial wall. Although isoflavonoids may 
prevent atherosclerosis development in postmenopausal 
women, little is known about their direct effects on ath-
erogenesis. Myasoedova and Sobenin (2008) showed that 
isoflavonoid-rich dietary supplement reduced the serum 
atherogenic potential in a double-blind placebo-controlled 
multicenter trial for the elucidation of anti-atheroslerotic 
activity of isoflavonoids.
Research on the effect of genistein on plasma nitric 
oxide concentrations, endothelin-1 levels and endothelium-
dependent vasodilatation in postmenopausal women 
revealed that genistein therapy improved flow-mediated 
endothelium-dependent vasodilatation in healthy post-
menopausal women. This improvement was mediated by 
a direct effect of genistein on vascular function and could be 
the result of an increased ratio of nitric oxide to endothelin 
(Sabudak and Guler, 2009).
Eff  ects on obesity; Regulation of adipogenesis
Experimental and epidemiological evidence has established 
an association between visceral obesity, a hallmark for the 
male obese phenotype, and metabolic syndrome, which 
retains its power throughout the spectrum of adiposity 
and is still clinically meaningful in severe obesity. The 
association may be due to an overload of liver free fatty 
acids produced by the high lipolitic activity of omental fat 
(Ørgaard and Jensen, 2008). Therefore men are usually at 
higher risk of cardiovascular disease than women (Stienstra 
et al., 2007). After menopause, the risk for women becomes 
similar to that for men because estrogen deficiency leads to 
visceral obesity, which is accompanied by a fall in insulin 
sensitivity and characterized by hyperglycemia and hyper-
lipidemia. Elevated blood lipid levels are closely associated 
with a very low-density lipoprotein VLDL and a low-density 
lipoprotein LDL cholesterol elevation and decreased levels 
of a high-density lipoprotein HDL cholesterol. E2 is a major 
regulator of adipocyte development and number in females 
and males. Due to structural similarities of isoflavones and 
E2, they can also influence the regulation of adipogenesis as 
a key process in obesity. 
Moreover, increasing evidence has established that 
isoflavones not only act through the estrogen receptors but 
also exert effects through numerous other pathways, such 
as those regulated by the peroxisome proliferator-activated 
receptor (PPAR). Adipogenesis is then regulated by the hor-
monally induced cooperative interaction between members 
of the enhancer binding protein and peroxisome prolifer-
ator-activated receptor (PPAR) families and the primary 
adipogenic transcription factors. They act by synergistically 
transactivating the expression of several adipogenic effector 
genes. Unlike the highly specific ERs, PPARs bind a wide 
number of ligands and directly affect lipid metabolism by 
enhancing transcription of PPAR-regulated genes (Shen 
et al., 2006). The results of comprehensive studies have 
suggested that isoflavones may exert inhibitory effects on 
adipose tissue enlargement. But especially in humans, the 
actions of soy isoflavones appear to depend on a complicated 
interaction between many factors, such as the presence of 217
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soy protein and particular intestinal bacteria (Ørgaard and 
Jensen, 2008). 
Despite the claims that link soy food consumption, 
through plasma cholesterol reduction, to a decreased risk 
of heart disease in humans, regular soy consumption did 
not significantly lower the LDL cholesterol in mildly hyper-
cholesteromic subjects, both equol or nonequol producers 
(Thorp et al., 2008). On the other hand, research on isofla-
vones and their effect on obesity in cell cultures, rodents and 
humans, suggests that a high isoflavone intake with a high 
soy protein intake leads to significantly greater decrease in 
serum total and LDL cholesterol (not HLD cholesterol) than 
does low isoflavone intake, demonstrating that isoflavones 
have LDL cholesterol-lowering effects and improve blood 
lipid profiles, at least when consumed in combination with 
soy proteins (Ørgaard and Jensen, 2008). 
Eff  ect of phytoestrogens on osteoporosis
Soy isoflavones may be useful in preventing and treat-
ing postmenopausal osteoporosis due to their similarity 
in structure to estradiol. They may thus act as potential 
replacements for estrogen deficiency. The implications of 
hormone replacement therapy in increasing the risk of heart 
disease and breast cancer have turned many women toward 
natural nutritional alternatives including phytoestrogens 
for the relief of menopausal symptoms and for preventive 
therapy of osteoporosis. Isoflavonoids and estrogens in 
hormone replacement therapies have overlapping yet some-
times divergent effects on the incidence of breast cancer 
and osteoporosis. Since stimulation of osteogenesis and 
concurrent inhibition of adipogenesis may explain the fact 
that estrogen deficiency decreases bone mass and increases 
adipose tissue, as seen in postmenopausal women, diets rich 
of isoflavonoids have positive effects on bone density and 
fracture rates (Ørgaard and Jensen, 2008). Isoflavonoids 
help to prevent osteoporosis by slowing down bone loss. 
Furthermore, several studies on soy supplementation 
and bone density suggest that soy products may be more 
effective in maintaining bone density in equol-producing 
individuals (Lampe, 2009). 
As isoflavonoids are lipophilic, they can cross cell 
membranes and bind to cytoplasmic ERs, which proceed 
to act as transcription factors. This leads to increased gene 
expression of alkaline phosphatases and osteocalcin (bone 
formation factor), osteoprotegerin (an inhibitor of osteo-
clast activity) and IGF (a promoter of osteoblast activity) 
resulting in reduced bone resorption and increased bone 
formation (Lockwood, 2008). 
Epidemiologic studies showed a positive association of 
soy intake and bone mass with increases in bone mineral 
density in the highest soy intake group. High consumption 
of soy isoflavones attenuated bone loss from lumbar spine 
of estrogen-deficient perimenopausal women. Erβ-specific 
targeting may produce beneficial effects in bones and may 
be applied as antiosteoporosis therapy in perimenopausal 
women (Chrzan and Bradford, 2007).
Daidzein was found to function as phytoestrogen in estro-
gen-responsive G-292 osterosarcoma cells. Transactivation 
studies with transfected ERs showed that this isoflavonoid 
was a potent activator of Erβ, though less potent than E2. 
Dadzein, like E2, inhibited IL-1β-cytokinin- and hormone-
mediated IL6 (interleukin-6; a multifunctional inflamma-
tory cytokine) secretion from G-209 osteosarcoma cell lines 
(Chrzan and Bradford, 2007). These results provide a basis 
for understanding how dietary phytoestrogens contribute 
to the osteoprotective effect without increasing the risk for 
breast cancer.
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